What is Gland Pharma?
Established in 1978 and headquartered in Hyderabad, India, Gland Pharma has evolved into a critical global manufacturer specializing in generic injectables. The company operates primarily through a business-to-business model, supplying high-quality oncology and ophthalmic products to over 60 countries. Its competitive advantage lies in its sophisticated R&D capabilities and a manufacturing footprint that adheres to stringent international quality standards. By focusing on complex injectable formulations, Gland Pharma addresses essential healthcare needs, positioning itself as a vital link in the global pharmaceutical supply chain.
How much funding has Gland Pharma raised?
Gland Pharma has raised a total of $200M across 1 funding round:
Unspecified
$200M
Unspecified (2013): $200M with participation from KKR & Co. L.P.
Key Investors in Gland Pharma
KKR & Co. L.P.
KKR is a global investment firm investing across private markets in every asset class all over the world. The firm is dedicated to fortifying companies and communities while helping secure the futures of the institutions and individuals counting on them.
What's next for Gland Pharma?
With this major enterprise-level funding, Gland Pharma is well-positioned to accelerate its growth trajectory and expand its portfolio of complex injectables. The strategic allocation of these funds will likely focus on scaling manufacturing capacity to meet rising global demand and deepening its penetration into highly regulated markets. As the company continues to refine its B2B strategy, the focus will remain on maintaining high-quality standards while optimizing production efficiencies. This capital deployment is expected to drive long-term value, enabling the firm to sustain its competitive edge in the oncology and ophthalmics segments while exploring new therapeutic frontiers.
See full Gland Pharma company page
